（责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 浙商证券研报指出，登康口腔近期公告披露2026年投资计划及《"8462"跃升行动—"十五五"战略规 划》，为公司未来成长明确方向。2026年公司积极投资开展"智改数转"并围绕口腔健康大健康主业开展 投资布局，拟计划投资金额约1.13亿元，其中固定资产投资约0.63亿元，股权投资约5000万元。"十五 五"聚力经营跃升，力争营业收入和利润总额双翻番。公司线上投入有望恢复、关注公司"十五五"开门 红。公司为抗敏牙膏领域绝对龙头，后续通过产品持续高端化升级及多元化品类布局，渠道端不断推进 即时零售等新兴渠道建设，在抖音等线上平台精益运营，积极利用直播电商的平台流量推新，后续增长 潜力充足。维持"增持"评级。 ...

Group 1: Health Products Business Performance - In the first half of 2025, the health products segment achieved revenue of 3.442 billion CNY, a year-on-year growth of 9.46% [2] - The segment focuses on a full-channel operation strategy, enhancing offline distribution and increasing online promotion efforts [2] - Key products include oral care toothpaste, which maintains a leading position, and hair care brand Yangyuanqing, which continues to grow driven by online sales [2][4] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment reported a main business revenue of 4.751 billion CNY in the first half of 2025, with a year-on-year increase of 10.8% [5] - Sales of Yunnan Baiyao aerosol exceeded 1.453 billion CNY, showing a significant growth of over 20.9% [5] - Other traditional Chinese medicine products also saw notable growth, with sales of Qianling Jianpi Granules surpassing 100 million CNY and Pudilan Anti-inflammatory Tablets nearing 100 million CNY [5] Group 3: Traditional Chinese Medicine Resource Business - The traditional Chinese medicine resource segment generated external revenue of 914 million CNY in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [6] - The segment implements a "six unifications" operational model to enhance the traditional Chinese medicine industry chain [7] Group 4: R&D and Innovation Progress - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative drugs [8] - In the first half of 2025, the company initiated phase III clinical trials for the prostate cancer diagnostic nuclear drug project INR101, with 60 subjects enrolled [9] - The innovative drug project INR102 for prostate cancer treatment received clinical trial approval, and phase I trials have commenced [9] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [10] - The total cash dividend for 2024, including special dividends, amounted to 4.279 billion CNY, representing 90.09% of the net profit attributable to shareholders [10] - In the first half of 2025, the company distributed a cash dividend of 10.19 CNY per 10 shares, totaling 1.818 billion CNY, which accounted for 50.05% of the net profit for that period [10]

Summary of Conference Call Records Industry Overview - The conference call discusses the food and beverage industry, focusing on various segments including alcoholic beverages, dairy products, snacks, and health products. Key Points and Arguments Alcoholic Beverages - The liquor sector, particularly the baijiu segment, shows strong resilience despite price fluctuations due to alcohol bans and online activities. Leading companies maintain price stability through channel power and policy adjustments, warranting attention to marginal fundamental changes in baijiu [1][4] - Other alcoholic beverages like beer, yellow wine, and pre-mixed drinks also exhibit high gross margins, typically between 40% to 60% [5] - The market share of pre-mixed drinks, such as those from Baijiu Holdings, has increased despite fierce competition, currently reaching 80% to 90% [6] Dairy Products - The dairy industry faces challenges due to reduced demand for social visits during the pandemic, leading to a lack of consumption scenarios. An increase in dairy cow inventory has resulted in oversupply, with smaller brands capturing market share through lower prices [7] - Price wars are intensifying, with retail prices for fresh milk and yogurt declining since 2021. Major brands like Yili and Mengniu maintain high margins on premium products, but ordinary products see margins drop to 20%-30% [7] Snack Industry - The snack sector is evolving with the rise of offline snack chains and online platforms like Douyin, creating new opportunities. However, consumers are highly price-sensitive, leading to reduced willingness to pay premiums [8] - Companies with high industrial efficiency and low costs, such as Salted Fish and Three Squirrels, are gaining market share by focusing on cost-effectiveness [8][9] Health Products - The health product sector is competitive, with customers willing to pay premiums for innovative products. Brands with new formulations and strong marketing capabilities can achieve higher premiums, while traditional brands like Tongrentang face challenges due to limited innovation [12] Consumer Behavior and Pricing - Consumers exhibit a willingness to pay higher prices for premium products in both self-satisfying and social contexts. Brands in the liquor sector, such as Moutai and Wuliangye, maintain high gross and net profit margins despite market fluctuations [4] - The willingness to pay for premium products is decreasing in the snack and health sectors, prompting leading companies to adapt their strategies [11] Investment Opportunities - Investment in the liquor sector is recommended, particularly in companies like Baijiu Holdings and Kweichow Moutai, which are currently undervalued [15] - The snack sector shows high growth potential, with companies like Wei Long and Salted Fish expected to maintain strong growth rates [15][16] - In the dairy sector, companies like New Dairy and Yili are highlighted for their innovative products and expected margin improvements [16] Emerging Trends - The pet economy is rapidly growing, with significant contributions from younger generations. Companies are expanding their presence in this market through new store openings and product offerings [17] - Health and personal care products are increasingly focusing on safety and health attributes, with brands like Weigao Medical leading in market share [18] Other Important Insights - The differentiation between "self-satisfying" (悦己消费) and "social" (悦人消费) consumption is emphasized, with the former relying on emotional needs and high-frequency repurchase, while the latter depends on cultural IP and seasonal demand [14][22] - Companies are encouraged to leverage technology and consumer trends to enhance user retention and product value [22]